Cargando…

Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses

Detalles Bibliográficos
Autores principales:	Climent, N, Munier, S, Piqué, N, García, F, Pavot, V, León, A, Primard, C, Miralles, L, Rovira, C, Casanova, V, McCormick, P, Gatell, JM, Verrier, B, Gallart, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441971/ http://dx.doi.org/10.1186/1742-4690-9-S2-P247

Ejemplares similares

Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8(+) T Cell Responses in HIV-1-Infected Individuals
por: Climent, Núria, et al.
Publicado: (2011)

P10-13. Increased production of alpha-defensins 1–3 by dendritic cells in HIV-infected individuals is associated with a slower disease progression rate
por: Rodriguez-Garcia, M, et al.
Publicado: (2009)

Induction of HIV mucosal immunity at distal sites after encapsulation of NOD1 and NOD2 ligands in biodegradable nanocarriers
por: Pavot, V, et al.
Publicado: (2012)

Adenosine Deaminase Enhances the Immunogenicity of Human Dendritic Cells from Healthy and HIV-Infected Individuals
por: Casanova, Víctor, et al.
Publicado: (2012)

Increased α-Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression
por: Rodríguez-García, Marta, et al.
Publicado: (2010)

P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02)
por: Gil, C, et al.
Publicado: (2009)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

P11-15. Induction of a mucosal immune response to HIV after systemic immunization with poly(lactic acid) nanoparticles formulated with gag antigen and polyI:C
por: Primard, C, et al.
Publicado: (2009)

P20-06. Study of viral variability evolution in patients submitted to a therapeutic vaccine based on autologous dendritic cells pulsed with autologous HIV-1
por: Guilà, M, et al.
Publicado: (2009)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
por: Saubi, N, et al.
Publicado: (2009)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Cellular immune responses and changes in VL after a Dendritic Cells (DC)-based therapeutic vaccine in cART treated chronic HIV-infected patients with CD4 T cells above 450/mm
por: García, F, et al.
Publicado: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
por: Ahmed, T, et al.
Publicado: (2012)

Newborn Mice Vaccination with BCG.HIVA(222) + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
por: Saubi, Narcís, et al.
Publicado: (2011)

Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4(+) T Cells From HIV-1 Patients
por: Xufré, Cristina, et al.
Publicado: (2022)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
por: Joachim, Agricola, et al.
Publicado: (2020)

Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms
por: Da Costa, David, et al.
Publicado: (2021)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study
por: Kann, Gerrit, et al.
Publicado: (2021)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
por: Aboud, S, et al.
Publicado: (2009)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

Analysis of transmitted HIV-1 drug resistance using 454 ultra-deep-sequencing and the DeepChek(®)-HIV system
por: Garcia-Diaz, Ana, et al.
Publicado: (2014)

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
por: Joachim, Agricola, et al.
Publicado: (2020)

Novel evidence for the nucleocytoplasmic shuttling of HIV-1 Tat by Importin13
por: Woods, Elena, et al.
Publicado: (2013)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
por: Mehendale, Sanjay, et al.
Publicado: (2013)

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
por: Nilsson, Charlotta, et al.
Publicado: (2015)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0uneiee4kt3rnbfjgpqck7ocjr